AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA therapeutics across several disease areas.
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA therapeutics across several disease areas.
